Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222442 | 0.87 | GRM5 (0.66) | GRM5KCNH2HDAC2S1PR1 | |
| SCHEMBL5225947 | 0.86 | GRM5 (0.53) | GRM5NPC1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL5226381 | 0.84 | GRM5 (0.64) | GRM5CHRNB2CHRNA5CHRNA4KCNH2 | |
| SCHEMBL4192844 | 0.80 | GRM5 (0.73) | GRM5CHRNB2CHRNA5CHRNA4KCNH2 | |
| SCHEMBL4190955 | 0.79 | GRM5 (0.65) | GRM5CHRNB2CHRNA5CHRNA4KCNH2 | |
| SCHEMBL4180789 | 0.79 | GRM5 (0.68) | GRM5CHRNB2CHRNA5CHRNA4KCNH2 | |
| SCHEMBL4197906 | 0.77 | GRM5 (0.68) | GRM5CHRNB2CHRNA5CHRNA4KCNH2 | |
| SCHEMBL4195255 | 0.77 | GRM5 (0.76) | GRM5CHRNB2CHRNA5CHRNA4KCNH2 | |
| SCHEMBL5223307 | 0.76 | GRM5 (0.46) | GRM5KCNH2S1PR1 | |
| SCHEMBL2072525 | 0.74 | HDAC2 (0.53) | HDAC2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885CHRNB2 117/4885CHRNA5 63/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885CHRNB2 117/4885CHRNA5 63/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885CHRNB2 117/4885CHRNA5 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.